{
  "id": "fat-derived-stem-cell-joint-therapy",
  "categoryId": "scientific-evidence",
  "subcategoryId": "treatments",
  "title": "Scientific Evidence for Fat Derived Stem Cell Joint Therapy",
  "shortTitle": "Fat-Derived Stem Cells",
  "tagline": "Adipose-derived stem cell injections for osteoarthritis with RCT support",
  "description": "A review of prospective and randomized studies using stromal vascular fraction and cultured adipose-derived MSCs for knee osteoarthritis.",
  "longDescription": "Multiple peer-reviewed trials have evaluated adipose-derived mesenchymal stem cells (ADMSCs) and stromal vascular fraction (SVF) for degenerative knee disease. Studies range from proof-of-concept Phase IIb RCTs to phase III double-blind trials, consistently reporting reductions in pain scores and improved WOMAC function versus placebo or hyaluronic acid at 6–12 months.",
  "alternativeTitles": [
    "SVF Knee OA Evidence",
    "Adipose MSC Clinical Data"
  ],
  "seo": {
    "metaTitle": "Scientific Evidence | Fat-Derived Stem Cell Joint Therapy",
    "metaDescription": "Explore the clinical trials behind adipose-derived stem cell injections for knee osteoarthritis, including randomized and placebo-controlled studies.",
    "keywords": [
      "adipose stem cell knee study",
      "stromal vascular fraction evidence",
      "fat derived stem cell osteoarthritis"
    ],
    "h1": "Fat-Derived Stem Cell Therapy: Clinical Evidence",
    "canonicalUrl": "/treatments/scientific-evidence/treatments/fat-derived-stem-cell-joint-therapy"
  },
  "hero": {
    "headline": "Evidence for Adipose-Derived Stem Cell Therapy",
    "subheadline": "Phase IIb–III data show meaningful pain and function gains in knee osteoarthritis.",
    "image": "https://images.unsplash.com/photo-1505751172876-fa1923c5c528?w=1920&q=80",
    "badge": "Clinical Research"
  },
  "quickStats": {
    "duration": "Day procedure",
    "anesthesia": "Local + light sedation",
    "downtime": "48-72 hrs",
    "resultsVisible": "6-12 weeks",
    "resultsLast": "12-24 months",
    "painLevel": "Low",
    "sessions": "Single injection (+ boosters if needed)"
  },
  "overview": {
    "title": "What the Literature Shows",
    "content": "Prospective studies report sustained pain reduction and functional improvement after intra-articular ADMSC or SVF injections. Randomized controlled trials versus placebo or hyaluronic acid demonstrate superior WOMAC and VAS scores at 6–12 months, with some MRI evidence of cartilage quality improvements.",
    "image": "https://images.unsplash.com/photo-1582719478250-c89cae4dc85b?w=1400&q=80",
    "highlights": [
      "Phase IIb and III RCTs against placebo and hyaluronic acid",
      "Measured endpoints: WOMAC, VAS pain, and MRI cartilage grading",
      "Follow-up windows from 6 months to 2+ years"
    ]
  },
  "howItWorks": {
    "title": "Why Fat-Derived Cells Help Joints",
    "subtitle": "SVF and cultured ADMSCs provide cushioning cells plus anti-inflammatory signalling.",
    "content": "Autologous adipose tissue is rich in mesenchymal stem cells, pericytes, and cytokines. When injected under ultrasound guidance, these cells can dampen inflammation, support cartilage matrix production, and improve shock absorption within the joint.",
    "variant": "default",
    "background": "default",
    "enabled": true,
    "benefits": [
      {
        "title": "Biologic cushioning",
        "description": "Adipose cells add volume and synovial support to reduce mechanical stress.",
        "icon": "circle-dollar-sign"
      },
      {
        "title": "Anti-inflammatory signalling",
        "description": "Paracrine factors modulate cytokines linked to OA pain and swelling.",
        "icon": "activity"
      },
      {
        "title": "Matrix support",
        "description": "MSCs can aid cartilage matrix turnover and may slow radiographic progression.",
        "icon": "grid"
      }
    ]
  },
  "whyChooseDrSNA": {
    "enabled": true,
    "title": "Why Our Approach",
    "subtitle": "Consultant-led protocols that mirror published methodology.",
    "items": [
      {
        "title": "Ultrasound guidance",
        "description": "Precise intra-articular placement mirrors trial protocols to optimise outcomes.",
        "icon": "crosshair"
      },
      {
        "title": "Standardised processing",
        "description": "Consistent SVF preparation to match doses used in published studies.",
        "icon": "settings"
      },
      {
        "title": "Rehab integration",
        "description": "Physiotherapy is aligned to the biological recovery window reported in trials.",
        "icon": "heart-pulse"
      }
    ]
  },
  "whatToExpect": {
    "enabled": true,
    "title": "What Studies Typically Report",
    "variant": "timeline",
    "steps": [
      {
        "title": "Baseline & Imaging",
        "description": "OA severity documented with radiographs or MRI; pain/function scored (WOMAC, VAS).",
        "icon": "scan"
      },
      {
        "title": "Single Injection",
        "description": "Ultrasound-guided intra-articular SVF or cultured MSC injection.",
        "icon": "syringe"
      },
      {
        "title": "Follow-up 3–12 Months",
        "description": "Pain and function reassessed; several trials show sustained improvements to 1–2 years.",
        "icon": "calendar-clock"
      }
    ]
  },
  "benefits": {
    "title": "Evidence Highlights",
    "items": [
      {
        "title": "Pain reduction vs placebo",
        "description": "Phase IIb RCTs show significant VAS and WOMAC pain improvements at 6–12 months.",
        "icon": "smile-plus"
      },
      {
        "title": "Functional gains",
        "description": "Trials report better WOMAC function and KOOS scores compared with hyaluronic acid.",
        "icon": "trending-up"
      },
      {
        "title": "Favourable safety",
        "description": "Reported adverse events are typically mild (transient soreness or swelling).",
        "icon": "shield-check"
      }
    ]
  },
  "faq": [
    {
      "question": "What outcomes did RCTs measure?",
      "answer": "Most randomized trials used WOMAC and VAS pain as primary endpoints, with follow-up between 6 and 12 months."
    },
    {
      "question": "How durable are results?",
      "answer": "Phase III data suggest benefits can persist beyond one year, with some cohorts reporting relief up to two years."
    },
    {
      "question": "Are there safety concerns?",
      "answer": "Studies report low complication rates—mainly temporary post-injection soreness—when using autologous adipose cells."
    }
  ],
  "cta": {
    "title": "Ready to Discuss SVF or ADMSC Therapy?",
    "subtitle": "Bring your imaging and goals—we will match them to the evidence.",
    "primaryButton": "Book a consultation",
    "secondaryButton": "Call the clinic"
  }
}
